Clinical Trial Update: QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy [Phase 1, Phase 2]

View source ↗

Summary

Update on QUILT-3.045, a Phase 1/2 trial of the NANT Merkel Cell Carcinoma vaccine in combination immunotherapy for patients with Merkel cell carcinoma who prog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Merkel Cell Carcinoma

Drugs mentioned

• NANT Merkel Cell Carcinoma (MCC) Vaccine

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Merkel Cell Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN